Quidel Reports Fourth Quarter and Full Year 2015 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Quidel Reports Fourth Quarter and Full Year 2015 Financial Results

SAN DIEGO, CA --(Marketwired - February 17, 2016) - Quidel Corporation ( NASDAQ : QDEL ), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2015.

Fourth Quarter 2015 Highlights:

  • Total revenues were $52.4 million as compared to $64.0 million in the fourth quarter of 2014.
  • Total influenza revenues decreased 33% from the fourth quarter of 2014 to $24.3 million.
  • Revenues from new products were 34% of total revenue in the fourth quarter.
  • Reported GAAP EPS of $(0.01) per share as compared to $0.20 per diluted share in the fourth quarter of 2014 and reported non-GAAP EPS of $0.10 per diluted share as compared to $0.37 per diluted share in the fourth quarter of 2014.

Full Year 2015 Highlights:

  • Total revenues increased by 7% to $196.1 million, as compared to $184.2 million in 2014.
  • Total influenza revenues increased 8% from 2014 to $88.4 million.
  • Revenues from new products increased 52% over 2014 to $57.3 million, and were 29% of total revenue.
  • Reported GAAP EPS of $(0.18) per share for the full year 2015 as compared to $(0.21) per share for the full year 2014 and reported non-GAAP EPS of $0.32 per diluted share for the full year 2015 as compared to $0.35 per diluted share for the full year of 2014.
  • Received 510(k) clearance from the FDA for the Solana instrumented molecular system and the Solana Group A Strep molecular assay, Quidel's first molecular instrumented system. 

Fourth Quarter 2015 Results Total revenues for the fourth quarter of 2015 were $52.4 million, versus $64.0 million in the fourth quarter of 2014. The 18% decrease in revenues was primarily due to lower sales of Infectious Disease products in the fourth quarter of 2015, due to a delayed and weaker flu season than in the fourth quarter of 2014.

Infectious Disease product revenues decreased 23% in the fourth quarter, led by lower sales of influenza and Group A Strep products. Total influenza revenues in the fourth quarter decreased 33% from the fourth quarter of 2014 to $24.3 million. Of the total influenza revenues, Sofia revenues made up 52%, QuickVue revenues accounted for 34%, and DHI Respiratory revenues were 14%. Over the same period, Women's Health revenues grew 6% to $9.3 million and Gastrointestinal revenues were flat at $1.8 million.

"Although we had three consecutive quarters of solid double-digit revenue growth and posted a record year for revenue, the delayed and weaker than expected influenza season, especially in the last few weeks of the year, meaningfully affected our fourth quarter growth," said Douglas Bryant, president and CEO of Quidel Corporation. "Even with quarterly gains in market share with Sofia, a weaker or delayed influenza season can have a significant impact on our fourth quarter results, which underscores the importance of our ongoing efforts to diversify our business. Despite a softer than normal end to the year, we believe that our company remains well-positioned for relatively near-term growth in both the emerging POC and molecular diagnostics categories, and are optimistic about our longer term opportunities."

Cost of Sales in the fourth quarter of 2015 decreased $3.1 million to $18.1 million, the result of decreased product revenue. Gross margin for the quarter was 65% as compared to 67% for the same period last year. R&D expense increased by $0.7 million in the fourth quarter as compared to the same period last year, primarily due to next generation immunoassay instrument development (Sofia 2). Sales and Marketing expense increased by $0.6 million in the fourth quarter of 2015, as compared to the fourth quarter of 2014 largely due to promotional activities for Virena, our cellular data management system. G&A expense increased by $0.5 million in the quarter, primarily due to an increase in compensation and professional services. 

Net loss for the fourth quarter of 2015 was $(0.4) million, or $(0.01) per share, compared to net income of $7.1 million, or $0.20 per diluted share, for the fourth quarter of 2014. On a non-GAAP basis, excluding amortization of intangibles, stock compensation expense and certain non-recurring items, net income for the fourth quarter of 2015 was $3.5 million, or $0.10 per diluted share, compared to $13.3 million, or $0.37 per diluted share, for the same period in 2014.

Full Year 2015 Results Total revenues for the twelve-month period ended December 31, 2015 were $196.1 million, as compared to $184.2 million for 2014. The 7% increase in revenue was primarily driven by stronger sales of Infectious Disease products in the first nine months of 2015, partially offset by weaker sales of Infectious Disease products in the fourth quarter of 2015.

Total influenza revenues for the year increased 8% to $88.4 million.

Cost of Sales for the full year 2015 decreased by $2.5 million over 2014 to $71.7 million due to the expiration of the amortization of the Alere settlement and improved manufacturing efficiencies. R&D expense for 2015 decreased by $2.4 million over last year due to decreased spend for the Savanna development program partially offset by increased investment in Sofia and Sofia 2 instrument systems and assays. Sales and Marketing expense increased by $4.8 million in 2015, primarily due to the full-year effect of the expansion and training of a larger sales force in 2015 relative to 2014. G&A increased by $3.6 million in 2015, primarily due to one-time expenses associated with business development activities that were incurred in the first quarter.

"In 2015, we launched Solana, our first instrument-based molecular platform, and met several internal milestones that should position us well for several new product introductions in the near- to medium-term," added Mr. Bryant. "In all, we had a solid year of product development and revenue growth, and expect to build on that foundation in 2016."

For the year ended 2015, net loss was $(6.1) million, or $(0.18) per share, compared to net loss of $(7.1) million, or $(0.21) per share, for the year ended 2014. On a non-GAAP basis, net income for the year ended 2015 was $11.2 million, or $0.32 per diluted share, compared to net income of $12.3 million, or $0.35 per diluted share, for the year ended 2014.

Non-GAAP Financial Information The Company is providing non-GAAP financial information to exclude the effect of stock-based compensation, amortization of intangibles and certain non-recurring items on earnings (loss) and net earnings (loss) per share as a supplement to its consolidated financial statements, which are presented in accordance with generally accepted accounting principles in the U.S., or GAAP.

Management is providing the adjusted net earnings (loss) and adjusted net earnings (loss) per share information for the periods presented because it believes this enhances the comparison of the Company's financial performance from period-to-period, and to that of its competitors. This press release is not meant to be considered in isolation, or as a substitute for results prepared in accordance with GAAP. A reconciliation of the non-GAAP financial measures to the comparable GAAP measures is included in this press release as part of the attached financial tables.

Conference Call Information Quidel management will host a conference call to discuss the fourth quarter and full year 2015 results as well as other business matters today beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). During the conference call, management may answer questions concerning business and financial developments and trends. Quidel's responses to these questions, as well as other matters discussed during the conference call, may contain or constitute material information that has not been previously disclosed.

To participate in the live call by telephone from the U.S., dial 253-336-7286, and enter the audience pass code 4449-7814.

A live webcast of the call can be accessed at http://ir.quidel.com , and the Web site replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) today by dialing 404-537-3406 from the U.S., or 855-859-2056 for international callers, and entering pass code 4449-7814.

About Quidel Corporation Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the QuickVue ® , D3 ® Direct Detection and Thyretain ® leading brand names, as well as under the new Sofia ® , AmpliVue ® , Solana ® and Lyra ® brands, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza , respiratory syncytial virus , Strep A, herpes, pregnancy, thyroid disease and  fecal occult blood . Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit quidel.com .

This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, fluctuations in our operating results resulting from seasonality, the timing of the onset, length and severity of cold and flu seasons, government and media attention focused on influenza and the related potential impact on humans from novel influenza viruses, adverse changes in competitive conditions in domestic and international markets, changes in sales levels as it relates to the absorption of our fixed costs, lower than anticipated market penetration of our products, the reimbursement system currently in place and future changes to that system, and changes in economic conditions in our domestic and international markets, the quantity of our product in our distributors' inventory or distribution channels, changes in the buying patterns of our distributors and changes in the healthcare market and consolidation of our customer base; our development and protection of intellectual property; our development of new technologies, products and markets; our reliance on a limited number of key distributors; our reliance on sales of our influenza diagnostics tests; our ability to manage our growth strategy, including our ability to integrate companies or technologies we have acquired or may acquire; intellectual property risks, including but not limited to, infringement litigation; limitations and covenants in our senior credit facility; our need for additional funds to finance our operating needs; volatility and disruption in the global capital and credit markets; acceptance of our products among physicians and other healthcare providers; competition with other providers of diagnostic products; adverse actions or delays in new product reviews or related to currently-marketed products by the U.S. Food and Drug Administration (the "FDA"); changes in government policies; compliance with other government regulations, such as safe working conditions, manufacturing practices, environmental protection, fire hazard and disposal of hazardous substances; third-party reimbursement policies; our ability to meet demand for our products; interruptions in our supply of raw materials; product defects; business risks not covered by insurance and exposure to other litigation claims; interruption to our computer systems; competition for and loss of management and key personnel; international risks, including but not limited to, compliance with product registration requirements, exposure to currency exchange fluctuations and foreign currency exchange risk sharing arrangements, longer payment cycles, lower selling prices and greater difficulty in collecting accounts receivable, reduced protection of intellectual property rights, political and economic instability, taxes, and diversion of lower priced international products into U.S. markets; our significant debt service requirements; the possibility that we may incur additional indebtedness; our ability to settle conversions of our convertible senior notes in cash; the effect on our operating results from the trigger of the conditional conversion feature of our convertible senior notes; dilution resulting from future sales of our equity; volatility in our stock price; provisions in our charter documents, Delaware law and the indenture governing our convertible senior notes that might delay or impede stockholder actions with respect to business combinations or similar transactions; and our intention of not paying dividends. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate," "plan," "intend," "goal," "project," "strategy," "future," and similar words, although some forward-looking statements are expressed differently. The risks described in reports and registration statements that we file with the Securities and Exchange Commission (the "SEC") from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision or update of these forward-looking statements, except as required by law.

   
QUIDEL CORPORATION  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(In thousands, except per share data; unaudited)  
   
    Three months ended December 31,  
    2015     2014  
Total revenues   $ 52,412     $ 63,953  
Cost of sales (excludes amortization of intangible assets from acquired businesses and technology)     18,122       21,263  
Research and development     9,939       9,199  
Sales and marketing     12,063       11,509  
General and administrative     7,408       6,862  
Amortization of intangible assets from acquired businesses and technology     2,218       2,205  
Total costs and expenses     49,750       51,038  
Operating income     2,662       12,915  
Interest expense, net     (2,989 )     (820 )
Income (loss) before provision for taxes     (327 )     12,095  
Provision for income taxes     50       4,982  
Net (loss) income   $ (377 )   $ 7,113  
                 
Basic (loss) earnings per share   $ (0.01 )   $ 0.21  
Diluted (loss) earnings per share   $ (0.01 )   $ 0.20  
                 
Weighted shares used in basic per share calculation     33,522       34,602  
Weighted shares used in diluted per share calculation     33,522       35,761  
                 
Gross profit as a % of total revenues     65 %     67 %
Research and development as a % of total revenues     19 %     14 %
Sales and marketing as a % of total revenues     23 %     18 %
General and administrative as a % of total revenues     14 %     11 %
                 
Condensed balance sheet data (in thousands):   12/31/2015     12/31/2014  
Cash, cash equivalents and restricted cash   $ 191,534     $ 204,022  
Accounts receivable, net     18,398       34,466  
Inventories     26,388       24,763  
Total assets     406,505       447,411  
Long-term debt     147,329       142,575  
Stockholders' equity     218,676       245,011  
                 
   
QUIDEL CORPORATION  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(In thousands, except per share data; unaudited)  
   
    Twelve months ended December 31,  
    2015     2014  
Total revenues   $ 196,129     $ 184,158  
Cost of sales (excludes amortization of intangible assets from acquired businesses and technology)     71,688       74,180  
Research and development     35,514       37,913  
Sales and marketing     47,886       43,076  
General and administrative     29,447       25,811  
Amortization of intangible assets from acquired businesses and technology     8,856       8,828  
Impairment loss     -       3,558  
Total costs and expenses     193,391       193,366  
Operating income (loss)     2,738       (9,208 )
Interest expense, net     (12,035 )     (1,775 )
Loss before benefit for income taxes     (9,297 )     (10,983 )
Benefit for income taxes     (3,218 )     (3,909 )
Net loss   $ (6,079 )   $ (7,074 )
                 
Basic loss per share   $ (0.18 )   $ (0.21 )
Diluted loss per share   $ (0.18 )   $ (0.21 )
                 
Weighted shares used in basic and diluted per share calculations     34,104       34,451  
                 
Gross profit as a % of total revenues     63 %     60 %
Research and development as a % of total revenues     18 %     21 %
Sales and marketing as a % of total revenues     24 %     23 %
General and administrative as a % of total revenues     15 %     14 %
                 
   
QUIDEL CORPORATION  
Reconciliation of Non-GAAP Financial Information  
(In thousands, except per share data; unaudited)  
   
    Three Months Ended  December 31,     Twelve Months Ended  December 31,  
    2015     2014     2015     2014  
    (unaudited)     (unaudited)  
Net (loss) income - GAAP   $ (377 )   $ 7,113     $ (6,079 )   $ (7,074 )
Add:                                
  Non-cash stock compensation expense     1,706       1,952       7,419       6,724  
  Amortization of intangibles     2,367       4,988       10,091       17,435  
  Impairment loss     -       -       -       3,558  
  Amortization of debt discount and issuance costs     1,351       292       5,340       292  
  One-time business development expenses     -       -       2,390       -  
  Income tax impact of valuation allowance for deferred tax assets and release of reserve for uncertain tax positions     (34 )     1,378       756       1,378  
  Income tax impact of non-cash stock compensation expense, amortization of intangibles, impairment loss, debt discount and issuance costs and one-time business development expenses     (1,520 )     (2,387 )     (8,733 )     (9,971 )
Adjusted net income   $ 3,493     $ 13,336     $ 11,184     $ 12,342  
Basic earnings per share:                                
    Adjusted net earnings   $ 0.10     $ 0.39     $ 0.33     $ 0.36  
    Net (loss) earnings - GAAP   $ (0.01 )   $ 0.21     $ (0.18 )   $ (0.21 )
Diluted earnings per share:                                
    Adjusted net earnings   $ 0.10     $ 0.37     $ 0.32     $ 0.35  
    Net (loss) earnings - GAAP   $ (0.01 )   $ 0.20     $ (0.18 )   $ (0.21 )
                                 

Quidel Contact: Quidel Corporation Randy Steward Chief Financial Officer 858.552.7931 Media and Investors Contact: Quidel Corporation  Ruben Argueta  858.646.8023 Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 110

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
LNG’s Coming Glut Could Gut Global Trading Profits

Updated Category News Views 33

A five-year LNG surplus is the sort of forecast that makes people nod politely today and panic much too late. Bain & Company is putting a hard edge on that risk: the global trading profit pool could slide from an estimated $20 billion in 2026 to roughly $5.5 billion a year during a 2030–34 glut, then potentially tip below zero once cancellation costs bite. That is not a...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 126

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Discount Tire’s $10 Correction Matters This Black Friday

Updated Category News Views 72

A ten-dollar correction is not a catastrophe, but it is precisely the sort of loose screw that deserves a glance before Black Friday shouting gets underway. Discount Tire says an earlier version of its Nov. 17, 2026 promotion release listed combined instant savings of $390 when the correct maximum is $380. The company issued the correction and supplied a revised release....

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 34

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 0

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Shenzhen’s APEC Moment Puts Pacific Trade Links in Focus

Updated Category News Views 80

A city that once logged eight stock trades in a day is hosting APEC with a very different kind of ledger in view. Shenzhen Stock Exchange began trial operations on December 1, 1990 with one stock, eight trades and roughly 200,000 yuan in turnover. By the end of September 2026, it had 2,908 listed companies and about 42.43 trillion yuan in combined market value. That is...

Continue Reading
American Pride Bank Tests a Fast Southeast Expansion

Updated Category News Views 154

Those old Winston-Salem smokestacks make a fitting backdrop for a bank trying to build something new, and American Pride Bank is moving with uncommon speed. Its new office at 450 N. Patterson Ave., Suite 200 sits in the Bailey South building in Innovation Quarter, across from Bailey Park and amid a district deliberately remade for founders, researchers and growing...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 203

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
2027 Auto Brand Awards Put Long-Term Buyer Value First Again

Updated Category News Views 32

Car shoppers staring down high prices and financing costs do not need another shiny badge; they need some help separating durable value from showroom wallpaper. That is why the 2027 U.S. News vehicle brand awards, announced Nov. 19, 2026, are worth a look. They are not a sales forecast, not a profit forecast, and certainly not a reason to blindly crown a corporate winner....

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating Trailblazers: Equity Prime Mortgage’s TAG 2025 Awards

Updated Category News Views 146

Recognizing Industry Innovators at TAG 2025 Awards spotlight collaboration, innovation, and empowerment shaping the next era of mortgage leadership. Equity Prime Mortgage (EPM), a prominent independent mortgage lender, has unveiled the winners of The American Gift (TAG) 2025 awards, honoring rising stars and leaders in the mortgage industry. During the event, founder and...

Continue Reading
GDS Holdings Set to Announce Q1 2025 Financial Performance

Updated Category News Views 144

GDS Holdings to Announce its First Quarter 2025 Financial Results GDS Holdings Limited, a prominent player in high-performance data center development and operations, is gearing up to share its financial performance for the first quarter of 2025. The announcement is expected to take place shortly before the opening of the U.S. market on May 20, 2025. As an investor and...

Continue Reading
Vineyard Workforce Insights: Skills and Opportunities Ahead

Updated Category News Views 152

Understanding the Vineyard Workforce A groundbreaking survey into the vineyard workforce has been conducted, collecting responses from nearly 1,700 workers. This survey stands as the most extensive study of its kind, yielding fascinating insights into job satisfaction, career aspirations, and the financial landscape of vineyard employees. Insight into Job Satisfaction...

Continue Reading
Explore the New Trading Opportunities with IDEX Biometrics

Updated Category News Views 126

Exciting Developments for IDEX Biometrics ASA Investors Recent efforts by IDEX Biometrics ASA have resulted in noteworthy advancements for its investors. With a strategic focus on growth and innovation, the company has successfully completed a private placement followed by a subsequent offering, significantly enhancing its financial posture. Overview of the Private...

Continue Reading
Celebrate Organic Month with Natural Grocers' Exciting Offers

Updated Category News Views 56

Celebrate Organic Month at Natural Grocers This September This September, Natural Grocers invites everyone to join in the festivities of Organic Month, featuring fantastic discounts, educational programs, and opportunities for fundraising. From September 12 to 14, customers can enjoy three days filled with amazing savings, samples, and freebies, making it the ideal time...

Continue Reading